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Abstracts / International Journal of Surgery 11 (2013) 589e6856040219: A CLOSED LOOP AUDIT TO ANALYSE AND IMPROVE COMMUNICA-
TION WITHIN THE BREAST CANCER MULTIDISCIPLINARY TEAM
SophieMarett, ThomasMicic, Chris Gateley. Royal Gwent Hospital, Cardiff, UK.
Background: Communication within any multidisciplinary team is critical
to ensure best patient care. ‘Best Practice Diagnostic Guidelines for Patients
presenting with Breast Symptoms' (1) state that ‘there should be clear and
rapid communication between breast imaging and the breast clinic'. This
continuing audit analyses and improves communication between breast
clinicians and radiologists, through the use of palpation scores (ranging
from 1¼normal to 5¼malignant) on radiology request forms.
Methods: The breast ultrasound radiology request forms over a 3 week
period were analysed as to whether palpation scores as per guidelines
were included. At initial audit presentation, the communication of breast
score guidelines on request forms was advocated and a new speciﬁc
radiology request form introduced. Re-audit was carried out prospectively.
Results: 87 patients required an USS over 3 weeks. 21.8% (n¼19/87) had
guideline-standard appropriate information. A prospective re-audit
demonstrated an initial improvement to 76%. An additional prospective re-
audit, after the implementation of a new radiology request form,
demonstrated a further improvement to 92%.
Conclusions: Communication in the MDT is paramount to ensure the best
care for cancer patients. The changes we have implemented, although
simple, have proven to be effective and can be easily extrapolated to other
similar clinical scenarios.
0292: AN ANALYSIS OF A NATIONWIDE SURVEY OF CURRENT TREND IN
BREAST RECONSTRUCTION
Debasish Debnath, Kamaljeet S. Samra, Lauren A.M. Mitchell, Lorna Cook,
Amy Burger, Isabella Karat, Ian J. Laidlaw, Raouf Daoud. Frimley Park
Hospital, Frimley, UK.
Aims: We aimed to assess whether recent wider use of acellular dermal
matrix (ADM)-based breast reconstruction affected other methods of
breast reconstruction.
Methods: An email-based survey, using surveymonkey.com, was per-
formed of all members of the Association of Breast Surgeons.
Results:Out of 438 members, 36 replied. 31 performed reconstruction, 29 of
whomwere breast surgeons.16 surgeons worked in tertiary centres,15 were
based in district general hospitals. Occurrences of different methods per-
formed during last year were compared with those of the preceding year.
There was a signiﬁcant fall in use of free ﬂap (14.03%, p<0.00000001) and
Latissimus Dorsi ﬂap (18.5%; p<0.00000001), and a rise of implant-only
(19.91%; p¼0.00002), ADM (69%; p¼0.000006) and other breast reconstruc-
tion methods (such as fat transfer) (279.16%; p¼0.09). Commonest compli-
cations encountered in ADM-based reconstructions were 1 to 2 cases of
allergy (n¼4), signiﬁcant bleeding (n¼2), infection (n¼13) and explantation
(n¼14). ADM of porcine origin was used mostly (n¼19). Funding (never¼6;
sometimes¼5) and faith related issues (never¼14; sometimes¼1) in using
ADMwere limited.
Conclusions: Admittedly a small response, although not so unexpected in
email-based surveys, conﬁrmed the trend of change in different methods
used in breast reconstruction. This has implications on training, organi-
sation and need for further research.
0316: NEOADJUVANT SYSTEMIC THERAPY FOR ER+ BREAST CANCER: IS
IT SAFE TO ASSESS THERAPY RESPONSES BASED ON IMMUNOHISTO-
CHEMICAL ASSESSMENT OF MOLECULAR SUB-TYPING?
Tasadooq Hussain, Kartikaye Grover, Tapan Mahapatra, Penelope McManus,
Amandeep Dhadda, Peter Kneeshaw. Castle Hill Hospital, Hull, UK.
Background: Hormonal status determined on immunohistochemistry is
considered as a surrogate of breast molecular subtypes. Neoadjuvant ther-
apy responses for the the luminal molecular subtype is determined on IHC
recognised ER+surrogates. With recent studies reporting discordance be-
tween IHC and gene expressionproﬁlingmolecular taxonomies, assessment
of therapy responses based on IHC surrogates may be questioned.
Aim: The aim of this study was to assess pCR & clinical response rates to
anthracycline-taxane neoadjuvant chemotherapy based on immunohis-
tochemical assessment of breast molecular subtypes.
Material and Methods: A retrospective analysis was performed of the
clinical and pathological data for 58 patients treated with Epirubicin
Cyclophosphamide-Docetaxel between January 2009 to December 2011.Statistically signiﬁcant correlations between pCR rates and molecular
subtypes were determined using chi-square test.
Results: A statistically signiﬁcant correlation with pCR (P¼0.03) and par-
tial clinical response (P¼0.04) was found with luminal-A and erbB2 sub-
types. An overall pCR rate of 9.6% was observed across all molecular
subtypes. An overall partial clinical response rate based on histological
subtype was 64% but considerably low in invasive lobular cancers.
Conclusions: Our study showed pCR and partial clinical response rates
were signiﬁcantly associated with luminal and erbB2 subtypes. A good
concordance rate was observed between IHC surrogates (ER+) of luminal
molecular subtype with regards to pCR rates.0317: AUDITING COMPLIANCE WITH NICE CLINICAL GUIDELINE: QUAL-
ITY STANDARD FOR BREAST CANCER (AUG 2011) AT SALFORD ROYAL
FOUNDATION TRUST (SRFT)
Stacey Picart. Salford Royal Foundation Trust, Manchester, UK.
Aims: To improve the care of patients with breast cancer. To determine
whether the Breast unit at Salford Royal Foundation Trust is compliant
with the most recent NICE Quality Standard for breast cancer care
guidance.
Methods: Breast Unit practice was compared against the NICE Clinical
Guideline: Quality standard for breast cancer (Aug 2011) for those patients
diagnosed with breast cancer at SRFT between September 2011 and
December 2011. Standard 1 was not included as it applies to primary care
institutions. Standard 10 was also excluded as not enough time had
elapsed between when the guidelines were published and when the audit
was carried out to determine whether mammography recommendations
were followed. Data was collected using the electronic patient records
system (iSoft).
Results: The trust achieved 100% compliance in 6 out of 10 key areas. Areas
identiﬁed for improvement included improving documentation about
reconstruction discussions, giving patients written care plans and doc-
umenting discussions about adjuvant therapy.
Conclusions: It was concluded that it may be beneﬁcial to have an elec-
tronic proforma that can be started at the time of a patient's diagnosis and
continually updated at each clinic or inpatient visit to ensure that all as-
pects of the guidance are covered.0318: COMPARATIVE PROTEOMIC APPROACH FOR THE IDENTIFICATION
OF PUTATIVE BIOMARKERS OF NEOADJUVANT CHEMOTHERAPY RESIS-
TANCE IN LUMINAL A BREAST MOLECULAR SUBTYPE
Tasadooq Hussain 1, Lucy Scaife 2, Victoria Hodgkinson2, Vijay Agarwal 2,
Tapan Mahapatra 1, Penelope McManus 1, Peter Kneeshaw1, Mike Lind 2,
Lynn Cawkwell 2. 1Castle Hill Hospital, Hull, UK; 2University of Hull-HYMS,
Hull, UK.
Background: Neo-adjuvant chemotherapy has become a standard treat-
ment for locally advanced breast cancer. However, resistance to chemo-
therapy can be a major obstacle in delivering an effective neo-adjuvant
treatment in oestrogen receptor positive breast cancers.
Aims: We aimed to expand the list of identiﬁed putative biomarkers of
neo-adjuvant chemotherapy resistance using fresh tumour samples in a
combined (antibody microarray and 2Dgels and mass spectrometry) pro-
teomic approach. Selected proteins from the panel will be taken forward
for pilot clinical validations using a pre-treatment archival samples series
to conﬁrm the clinical relevance.
Materials and Methods: Invasive ductal oestrogen positive (luminal
subtype) tumour samples were selected after receiving anthracycline
neoadjuvant therapy. A total of 9 antibodymicroarray & three 2D-gels with
mass spectrometry proteomic experiments were performed. Differential
protein expression was compared between chemotherapy resistant and
sensitive tumours. The combined data from all experiments was analysed
using Ingenuity Pathway Analysis (Ingenuity Systems).
Results: A tota of 141 differentially expressed proteins were identiﬁed
using the combined approach. Of these,17 proteins were found in at least 2
or more experiments.
Conclusion: In addition to our previously identiﬁed panel of biomarkers
from the pilot series, we have now identiﬁed a further 14 proteins that
could potentially have a role as predictive biomarkers of neo-adjuvant
chemotherapy resistance in breast cancer.
